奇利辛囊改善了DOCA盐诱导的心脏功能障碍的老鼠的心脏重塑
1China Science and Technology Development Center for Chinese Medicine, Beijing, China. houyunlonghrb@hotmail.com.
European review for medical and pharmacological sciences
|August 22, 2023
概括
奇利辛囊 (QL) 改善了心脏功能,并减少了HFpEF心力衰竭的老鼠模型中的纤维化. 通过减轻心脏重塑和炎症,QL显示出保护作用.
科学领域:
- 心血管研究研究心血管研究
- 药理学 药理学是指药理学的学科.
- 传统中国医药 传统中国医药
背景情况:
- 保存喷射分数的心力衰竭 (HFpEF) 是一种复杂的心血管疾病,治疗选择有限.
- 脱氧皮质乙酸盐 (DOCA) 盐诱导的老鼠模型模仿了HFpEF的关键病理特征,包括心脏重塑和腹功能障碍.
- 研究新型治疗药物,如Qiliqiangxin囊 (QL) 对于开发有效的HFpEF治疗方法至关重要.
研究的目的:
- 评估Qiliqiangxin囊 (QL) 在脱氧皮质乙酸盐 (DOCA) 盐诱导的心力衰竭与保存喷射分数 (HFpEF) 的小鼠模型中的保护作用.
- 在这个HFpEF模型中阐明QL心脏保护作用背后的作用机制 (MOA).
主要方法:
- 60只Sprague Dawley大鼠接受了DOCA盐治疗,以诱导HFpEF,并分为模型,萨库比特里尔瓦尔萨坦 (Sac/Val),低剂量Qiliqiangxin (QL-L) 和高剂量Qiliqiangxin (QL-H) 组.
- 用血压,NT-proBNP水平,心脏指数,心声回声和血液动力学来评估心脏功能.
- 心脏纤维化,心肌细胞大小和参与心脏重塑和炎症 (TGF-β1,MMPs,NF-κB,Smads) 关键蛋白质的表达被使用马森染色,WGA染色和西方染色分析.
主要成果:
- 与模型组相比,Qiliqiangxin囊治疗显著改善了心脏功能,可以通过增加喷射率 (EF),改善E/A比率,降低心脏指数和降低NT-proBNP水平来证明.
- QL的使用抑制了心肌纤维化和心肌细胞缩,正如Masson和WGA染色所示,并降低了心脏重塑标记物的表达 (TGF-β1,MMP2,MMP9,Smad2,Smad3).
- QL降低了NF-κB的表达,减少了促炎性细胞因子 (TNF-α,IL-2) 和增加了抗炎性细胞因子 (IL-10) 水平,表明存在抗炎机制.
结论:
- 在DOCA盐诱导的老鼠HFpEF模型中,Qiliqiangxin囊显示出显著的心脏保护作用.
- QL通过增强腹功能,预防左心室缩和减少心肌纤维化来改善心脏功能.
- 保护机制包括改善炎症反应和调节参与心脏重塑的关键信号通路.
相关概念视频
01:22Heart Failure Drugs: Diuretics
420
Heart failure and kidney perfusion are interconnected in a complex way. Reduced renal perfusion and venous congestion are two significant factors that contribute to renal dysfunction in heart failure. The kidneys, primarily responsible for fluid balance in the body, are adversely affected due to compromised cardiac output and increased venous pressure. In response to reduced renal perfusion, the kidneys activate neurohumoral mechanisms to restore balance. However, these mechanisms can be...
420
01:26Heart Failure Drugs: Inhibitors of Renin-Angiotensin System
463
The activation of the sympathetic nervous system and the renin-angiotensin-aldosterone system (RAAS) contributes to cardiac remodeling, and inhibiting the RAAS is a pharmacological target in heart failure management. As a result, neurohumoral modulation is a crucial treatment principle for managing heart failure. This approach involves using medications like ACE inhibitors (ACEIs), angiotensin receptor blockers (ARBs), β-blockers, mineralocorticoid receptor antagonists (MRAs), and neutral...
463
01:29Cardiomyopathy V: Interprofessional Care
16
Managing cardiomyopathy involves addressing underlying or precipitating causes, treating heart failure with medications, and implementing dietary changes and a balanced exercise and rest regimen.Lifestyle ModificationsCardiomyopathy patients should adopt a low-sodium diet to reduce fluid retention and manage heart failure. A personalized exercise and rest plan helps maintain physical fitness without overstraining the heart. Avoiding alcohol and tobacco is essential to prevent further damage to...
16
01:30Cardiomyopathy II: Dilated Cardiomyopathy
11
Dilated cardiomyopathy, or DCM, is a progressive myocardial disorder characterized by ventricular chamber dilation and contractile dysfunction.EtiologyVarious factors can cause DCM, including hypertension and heavy alcohol intake, which contribute to the weakening and enlargement of the heart muscle. Viral infections, such as Coxsackievirus B, adenoviruses, and influenza, can lead to DCM by causing inflammation and damage to heart tissue. Certain chemotherapeutic agents, including daunorubicin,...
11